They are available in large formats up to 10 feet wide and nearly unlimited lengths.  

Until that number is zero, we have more work to do. NOx: 0.25 MT 2. PSIC: 0 2.

IATF Certificate Place and date: For the issuing office: Katy, TX, 10 December 2024 Revision 2 DNV - Business Assurance 1400 Ravello Drive, Katy, TX, 77449- 5164, USA Sherif Mekkawy Management Representative Lack of fulfilment of conditions as set out in the Certification Agreement may render this Certificate invalid. ACCREDITED UNIT: DNV Business Assurance USA Inc., 1400 Ravello Drive, Katy, TX, 77449-5164, USA - TEL: +1 281-396-1000. www.dnv.com Page 1 of 2 MANAGEMENT SYSTEM CERTIFICATE Certificate no.: 273138-2018-AQ-RGC-IATF IATF Certificate No: 0558323 Valid: 10 December 2024 – 09 December 2027 This is to certify that the management system of Polyone - Shenzhen Co., Ltd. ACCREDITED UNIT: DNV Business Assurance USA Inc., 1400 Ravello Drive, Katy, TX, 77449-5164, USA - TEL: +1 281-396-1000. www.dnv.com Page 2 of 2 Appendix to Certificate Polyone - Shenzhen Co., Ltd.

Great Place Special items, tax adjustments(2) 2)

They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Continue fostering our Great Place to Work® culture Strategic ObjectivesStrategic Objectives Long Term Growth Rates Growth DriversGrowth Drivers $340 $455 $790 $1,175 2016 2018 2020 2022 $51 $84 $212 $668 2016 2018 2020 2022 $108 $113 $231 $293 2016 2018 2020 2022 $265 $358 $726 $830 2016 2018 2020 2022 8-12% 10% 8-10% 5% Sustainable Solutions Composites Healthcare Asia/Emerging Regions Profitable GrowthProfitable Growth Great Place to WorkGreat Place to Work 5.4% 11.5% 16.2% 2006 2018 2022 EBITDA Margins $0.14 $2.67 $3.04 2006 2018 2022 Adjusted EPS 2022 data is pro forma for acquisition of Avient Protective Materials and Distribution divestiture TO P- T IE R S US TA I NA B I L I TY PE R F OR MA N C E A N D R EC O G NI T I ON Industry Sustainability Standards 90th percentile 87th ESG Ratings Performance 2 2 5 5 Innovation is the lifeblood of a specialty company. expectations: US & Canada LATAM EMEA Asia • Net price benefit remains greater than wage and energy inflation • Clariant synergies and reduced administrative costs Q2 2 023 SEQUENTI AL SAL ES BY REGI ON Q 2 2 0 2 3 v s .

This will require a massive investment and deployment of smaller antennas and fiber optic cables strategically placed close together to deliver its intended performance," said Over the next decade as infrastructure is put in place, we expect double-digit revenue growth of our composite solutions, which includes 5G applications." High-frequency 5G networks rely on the densification of transmission antennae, resulting in an increased number of fiber optic cables and components capable of performing in harsh conditions. 

Approved Corporate : Manual Document #: DOC-02627 Revision: 6 Document Owners: Kyle Johnson Effective Date: Mar 20, 2024 Title: Global Supplier Quality Manual Page 2 of 10 Only the electronic version of this document in ETQ is the controlled version of the document. All packaged raw materials shall include the Avient raw material SAP code number and will not be compromised. Supplier containment shall take place without undue delay to avoid additional defective material shipment.

Microsoft PowerPoint - AVNT June IR Conferences_6.1.2023 1130AM AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) J U N E 2 0 2 3 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Continue fostering our Great Place to Work® culture Strategic ObjectivesStrategic Objectives Long Term Growth Rates Growth DriversGrowth Drivers $340 $455 $790 $1,175 2016 2018 2020 2022 $51 $84 $212 $668 2016 2018 2020 2022 $108 $113 $231 $293 2016 2018 2020 2022 $265 $358 $726 $830 2016 2018 2020 2022 8-12% 10% 8-10% 5% Sustainable Solutions Composites Healthcare Asia/Emerging Regions Profitable GrowthProfitable Growth Great Place to WorkGreat Place to Work 5.4% 11.5% 16.2% 2006 2018 2022 EBITDA Margins $0.14 $2.67 $3.04 2006 2018 2022 Adjusted EPS 2022 data is pro forma for acquisition of Avient Protective Materials and Distribution divestiture TO P- T IE R S US TA I NA B I L I TY PE R F OR MA N C E A N D R EC O G NI T I ON Industry Sustainability Standards 90th percentile 84th ESG Ratings Performance 3 1 5 5 Innovation is the lifeblood of a specialty company.

Customer collaboration and feedback has been extremely positive, and cultural integration has been excellent, as evidenced by the employee engagement scores that clearly reflect Avient is a great place to work. To participate in the audio-only portion of the call, dial 1-844-835-7433 (domestic) or 1-914-495-8589 (international) and provide conference ID number 3293155. To listen to this recording, dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and provide conference ID number 3293155.

APPLICATIONS • Medical devices • Drug delivery devices • Labware KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* * FDA/EU compliance information available upon request Copyright © 2023, Avient Corporation. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.